Intratumoral heterogeneity greatly hinders efficiency of target therapy in glioblastoma (GBM). To decipher the underlying mechanisms of heterogeneity, patient-derived adult GBM cells were separately isolated from margins of T1 gadolinium enhancing tumor lesions (PNCs) and T1 gadolinium enhancing core lesions (ECs). Single clone culture was conducted in ECs and U87MG cell line to screen clones with distinct biological phenotypes. Single cell clones with diverse phenotypes were simultaneously separated from ECs and U87 cell line. PNCs, GCs(H) and U87(H) exhibited longer cellular protrusion than ECs, GCs(L) and U87(L), respectively. Cell strains with longer protrusion exhibited higher invasive ability and lower sensitivity to temozolomide (TMZ) and radiation. Subsequently, TPD52L2 was verified as the functional protein to regulate the cellular heterogeneity by the proteomics analysis. Downregulation of TPD52L2 enhanced cell invasion whereas inhibited cell proliferation rate and sensitivity to chemotherapy in vivo and in vitro, this condition was reversed when TPD52L2 was overexpressed. The invasiveness was facilitated by up-regulating CTNNB1/β-catenin and SNAI1/Snail mediated EMT process. In addition, the clinical data of 88 GBM cases in our neurosurgery center was analyzed to reveal the influence of TPD52L2 in the prognosis of GBM. Low expression of TPD52L2 exacerbated prognosis of GBM patients received standard radiotherapy plus concomitant and adjuvant TMZ (Stupp strategy). Taken together, TPD52L2 is an important biomarker influencing GBM prognosis.
Introduction
Glioblastoma (GBM) is the most common and deadly brain tumors in adults. Currently, despite radiotherapy plus adjuvant temozolomide (TMZ) following surgical resection for GBM prolong medial survival to 14.6 months (1), infiltrative nature of remained tumor cells after surgical resection easily induce the occurrence of chemo-radio resistance and exacerbate prognosis of GBM (2) . Given the exceedingly poor prognosis, it is critical to understand the biology of these residual chemo-radio resistant cells remained after surgical resection.
In GBM, epithelium-mesenchymal transition (EMT) has been reported to mediate chemo-radio resistance through autophagy, microRNAs-related circuits and activation of Wnt and TGF-β pathways (3) (4) (5) (6) (7) . EMT is a crucial process involved in the embryonic development and has been widely studied in the pathological contexts including wound healing, inflammation, cancer invasion and metastasis (8, 9) . During EMT program, cells transform from polarized epithelium like cells to spindle fibroblast cells and lose tight connection by switching from T-cadhein/R-cadherin to N-cadherin (10, 11) . Meanwhile, the intratumoral heterogeneity has provided another basis for GBM recurrence and chemo-radio resistance (12, 13) . It briefly encompass cellular genetic and phenotypic diversity inside tumor center and in the peripheral tumor tissue. More recently, the high resolution sequencing has revealed subtype-specific differences of molecular and cellular composition at center and margin of GBM, which drives the clonal evolution and tumor recurrence (14) (15) (16) (17) (18) . Besides, intratumoral heterogeneity has also been reported to involve in different chemotherapy response in other tumors including chronic lymphocytic leukemia and lung cancer etc (19) (20) (21) . However, the connection of EMT and intratumoral heterogeneity in GBM has rarely been studied up to now, and it is conceivable that key invasion pathways exerting influence in other cancers outside central nerve system might also exist in brain tumor.
To tackle these issues, we separated cell strains from margins of T1 gadolinium enhancing tumor lesions versus core lesions of T1 gadolinium enhancing zone, and acquired single cell clones from core lesions of T1 gadolinium enhancing zone. Same procedures were manipulated simultaneously in U87MG cell line for comparison. Our results demonstrated GBM are composed of cell clones with diverse phenotypes. In normal condition, the cell clone exhibiting lower invasive ability showed higher proliferation rate and lower apoptosis rate, the cell clone with higher invasive ability showed lower proliferation rate and higher apoptosis rate. However, this condition was reversed by TMZ and X-ray treatment. To decipher the intertwined mechanisms, proteomics analysis was conducted and a novel target, TPD52L2, was subsequently unearthed. Furthermore, we put forward TPD52L2 suppress GBM cell invasiveness in vitro and in vivo through inhibit CTNNB1/β-catenin and SNAI1/Snail mediated EMT. Meanwhile, we dissected the impact of TPD52L2 on GBM patient survival, unveiling its latent effect on tumor heterogeneity and therapy resistance.
Materials and methods

Cell line and culture
Tumor tissues were obtained from five patients pathologically diagnosed as GBM (WHO IV), informed consent were obtained and Institutional Review Board approval was granted. U87MG cells were purchased from the Chinese Academy of Sciences (Shanghai, China) in December 2013. Short tandem repeat loci and Amelogenin loci genotyping of this cell line was authenticated in January 2014. The detailed primary cell culture was documented in Supplemental Methods, available at Carcinogenesis Online.
Wound healing assay
Five pairs of PNCs, ECs, GCs(H) and GCs(L) isolated from five GBM patients and U87(H), U87(L) were employed in the experiment. Confluent cell monolayers were cultured in six-well plates and manually scratched with pipette tip. The monolayers were then washed twice with phosphate-buffered saline (PBS) to remove floating cells. Fresh or conditioned medium was then applied with or without TMZ as indicated. Images of the same wound area were photographed at 0, 12, 24 h for U87MG cell clones and 0, 24, 48, 72 h for primary cells, respectively.
For data analysis, images at time zero (t = 0 h) showed the initial area of the wounds, while the recovery of the wounded monolayers by cell migration toward the wound was analyzed at 12 h for U87MG cell clones and 48 h for primary cells, respectively (t = Δ h). The area of the wound was quantified using ImageJ software (version 1.48) with the polygon selection mode. The cells' migration area toward the wounds was calculated as following: wound closure =A (t = 0 h) -A (t = ∆h). All images analyzed were photographed at 100× magnification.
Transwell assay
Five pairs of PNCs, ECs, GCs(H) and GCs(L) isolated from five GBM patients and U87(H), U87(L) were employed in the experiment. The corresponding cells were trypsinized and counted, a total of 1 × 10 4 cells were aliquoted in 100 μl Dulbecco's modified Eagle's medium without fetal bovine serum and seeded on fibronectin-coated polycarbonate membrane inserts of transwell apparatus (Corning Inc., NY). In the lower chamber, 550 μl of conditioned medium was added as a chemoattractant. After the cells were incubated for 12 h at 37°C in incubator, the inserts were washed with PBS, and cells on the top surface of the inserts were removed with cotton swabs. Cells adhering to the lower surface were fixed with methanol, stained with 0.1% 4′6′-diamidino-2-phenilindole (DAPI) for 2 min (22) . Images were photographed at 100× magnification at six high-resolution predetermined fields. All assays were independently repeated at least three times.
Cell proliferation assay
Five pairs of PNCs, ECs, GCs(H) and GCs(L) isolated from five GBM patients and U87(H), U87(L) were employed in the experiment. Cell proliferation was measured by the colorimetric Cell Counting Kit-8 (CCK-8) assay (Dojindo, Kumamoto, Japan) according to the manufacturer's protocol. Briefly, the density of primary cells and cell clones were adjusted to 1000-5000 cells/well according to the corresponding growth pattern and duration of different experiments. After incubation for 12 h to allow cells to attach to the bottom of the wells, 10 μl CCK-8 solution was added to each well for consecutive 7 or 14 days every other day. And the plates were incubated at 37°C for 2 h before the absorbance was determined at 450 nm with a microplate reader.
Colony formation assays
Five pairs of PNCs, ECs, GCs(H) and GCs(L) isolated from five GBM patients and U87(H), U87(L) were employed in the experiment. Single cells in 0.6% top agar-medium were plated in triplicate onto 60-mm dishes (300 cells per dish) that had been pre-coated with 1.2% agar-medium before being treated with 200 μM TMZ and 4 Gy X-ray. Cells were incubated at 37°C, and the medium was replaced with fresh medium for every 3-4 days. Survived colonies were stained with crystal violet 3 weeks later and counted. The colony formation rate was calculated as follows: colony formation rate = (number of colony/inoculation cell number) × 100%.
TMZ and X-ray treatment
was obtained from Sigma-Aldrich Chemical Co. (Sigma, T2577) and was dissolved in dimethyl sulfoxide (DMSO) (Sigma, D2650). The dissolved TMZ was then aliquoted to 125 μl each at original concentration of 200 mM and stored in −80°C. The stock solution was diluted with Dulbecco's modified Eagle's medium according to the necessity of different experiments and filtered through a 0.22-μm cell strainer (Millipore, MA).
Cells were irradiated with 4Gy X-ray to mimic a clinically relevant GBM therapy. After radiation, cells were subjected to subsequent analysis. Irradiation was performed with an X-ray generator (120 kV, 22.7 mA, variable time; GE Inspection Technologies, Hürth, Germany).
Immunofluorescence
Five pairs of PNCs, ECs, GCs(H) and GCs(L) isolated from five GBM patients were employed in the experiment. 
Immunohistochemistry
All procedures were manipulated as described previously (6) . Sections were then incubated with TPD52L2 antibody (1:100, 11795-1-AP, Proteintech, Wuhan, China) overnight at 4°C and rinsed three times in 1× PBS to incubate with biotin-labeled goat anti-rabbit antibody (1:500, SA00004-2, Proteintech, Wuhan, China) for 30 min at room temperature. Lastly, the peroxidase reaction was developed using 3,3-diaminobenzidine (DAB) chromogen solution in DAB buffer substrate (BioLegend, CA). For evaluation of staining, the immunohistochemically stained tissue sections were reviewed and scored separately by two pathologists blinded to the clinical parameters. For cytoplasmic staining, the score was evaluated according to the sum of cytoplasm staining intensity and the percentage of positive staining cells. The staining intensity was scored as 0-3 as previously described (23, 24) and the percentage of positive staining cells was defined in a scale of 0-3 (0: 0-10%, 1: 10-25%, 2: 26-75% and 3: ＞76%). The sum of the cytoplasm scores were used as the final staining score (0-6). For statistical analysis, a final staining score of 0-3 and 4-6 in cytoplasm were considered to be low or high-expression levels, respectively.
Flow cytometric assay
Five pairs of PNCs, ECs, GCs(H) and GCs(L) isolated from five GBM patients and U87(H), U87(L) were employed in the experiment. Cell apoptosis was determined by utilizing an Annexin V/fluorescein isothiocyanate (FITC) apoptosis detection kit (BD Biosciences, NY). For cell apoptosis analysis, cells cultured in six-well plates were trypsinized, washed and stained with FITC-conjugated anti-Annexin V antibodies and Propidium Iodide staining solution simultaneously in the dark for 15 min at room temperature. For cell cycle analysis, cells were seeded in 60-mm dishes and cultured in Dulbecco's modified Eagle's medium without fetal bovine serum to synchronize cycles for 24 h. After incubation for another 72 h, a total of 5 × 10 5 cells were harvested, rinsed with cold phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol for 2 h at room temperature. Fixed cells were rinsed with cold PBS followed by incubation with binding buffer containing 0.5 mg/ml RNAase for 30 min at 37°C. Lastly, cell suspension was stained with 10 mg/ml propidium iodide in the dark for 15 min at room temperature. The apoptosis rate and DNA content of labeled cells was acquired using a FACSCaliber instrument (BD Biosciences, NY). Each experiment was performed in triplicate.
Recombinant lentivirus construction and transfection
ECs and GCs(L) isolated from five GBM patients and U87(L) were employed in the experiment. Non-specific control siRNA (NC) and two pairs of siRNA for human TPD52L2 (NM_199360) were purchased from GenePharma Co. (Shanghai, China). The TPD52L2 siRNA sequences were as follows: sense 5′-GGAGGGUUUGAAAGAAUAUTT-3′ and antisense 5′-AUAUUCUUUCAAACCCUCCGC-3′. To rule out the possible off-target effects of siRNA, another oligonucleotide sequence: sense 5′-CUACAAGAAGACUCAGGAATT-3′ and antisense 5′-UUCCUGAGUCUUCUU GUAGAG-3′ was used to get comparable results. The nonspecific control siRNA sequences were as follows: sense 5′-UUCUCCGAACGUGUCACGUTT-3′ and antisense 5′-ACGUGACACGUUCGGAGAATT-3′. Transfection was performed following the manufacturer's instructions using Lipofectamine 2000 reagent (Invitrogen Inc., Carlsbad, CA) when cells achieved 60-70% confluence. Transfection complexes were added directly to the cells at a final concentration of 100 nM siRNA and the medium was replaced 6 h post-transfection.
After validation of silencing effect of siRNA, sense 5′-GGAGGGUUUGAAAGAAUAUTT-3′ and antisense 5′-AUAUUCUUUCAAA CCCUCCGC-3′ was selected to insert into the lentiviral expression vector Lv EF-1a/luci05/Puro (GenePharma, Shanghai, China). Cells were seeded in six-well plates and transfected with TPD52L2 shRNA (Lv-shTPD52L2) and control shRNA (Lv-shCon) expressing lentivirus at a multiplicity of infection (MOI) of 200.
Stable TPD52L2 overexpression
PNCs and GCs(H) isolated from five GBM patients and U87(H) were employed in the experiment. Cells were infected with Lv5 SmaI-TPD52L2 (GenePharma, 161120AZ) or control Lv5 SmaI NC (GenePharma, 16-1923Z) . The infection efficiency was evaluated by western blot analysis. The stable cell lines were selected in puromycin (1 mg/ml; Sigma, P8833). The sequences of human TPD52L2 (NCBI Reference Sequence: NM_199360.2) was cloned into the Lv5 SmaI-TPD52L2 vector (GenePharma, Shanghai, China).
Two-dimensional gel electrophoresis
See Supplemental Method, available at Carcinogenesis Online.
Protein identification by mass spectrometry
Western blotting
The lysis protein were obtained from U87(H), U87(L) and five pairs of PNCs, ECs, GCs(H) and GCs(L) isolated from five GBM patients, respectively. Western blot analysis was performed as described previously (25) . Antibodies against SNAIL1 (C15D3, 9585), β-catenin (D10A8, 8480), N-Cadherin (D4R1H, 13116), GAPDH (14C10, 2118) (Cell Signaling Technology) were used at a concentration of 1:1000; anti-TPD52L2 antibody (11795-1-AP) (Proteintech, Wuhan, China) were used at 1:800. anti-CDH13/T-cadherin (sc-7940, SantaCruz, TX) was used at 1:300. Secondary anti-rabbit conjugated to HRP (AS014), (ABclonal, Wuhan, China) was then added at 1:5000. Proteins were visualized using Clarity ECL Western Substrate (Millipore, Hercules, CA).
Subcutaneous xenografts in vivo
Five pairs of PNCs, ECs, GCs(H) and GCs(L) isolated from five GBM patients were employed in the experiment. All the procedures followed the institutional and national guidelines for the care and use of animals and approved by the animal ethics committee of Nan Fang hospital. Lv-TPD52L2, TPD52L2(oe) and Lv-shCon primary cells were dissociated to single-cell suspensions, and 5 × 10 5 cells were implanted into the subcutaneous tissue of the left flank of 4-to 5-week-old NOD/SCID mice. Twenty-one days after cells implantation, mice were randomized to DMSO or TMZ cohorts. TMZ (10 mg/ kg; Sigma-Aldrich) or DMSO (Sigma-Aldrich) was injected i.p. for next seven consecutive days, then the mice were euthanized with sodium pentobarbital. The subcutaneous and neighboring tissues were carefully dissected and photographed. And samples from core and peripheral regions were dissected for paraffin embedding according to standard procedures. Tissue blocks were prepared for histology and immunohistochemistry (IHC) study.
Orthotopic xenografts in vivo
Five pairs of PNCs, ECs, GCs(H) and GCs(L) isolated from five GBM patients were employed in the experiment. All the procedures followed the institutional and national guidelines for the care and use of animals and approved by the animal ethics committee of Nan Fang hospital. Lv-TPD52L2, TPD52L2(oe) and Lv-shCon primary cells were dissociated to single-cell suspensions, and 1 × 10 6 cells were injected intracranially into 4-to 5-week-old NOD/SCID mice as described (26) . Three independent experiments with five mice per group in each experiment were done. One week after cells implantation, mice were randomized to DMSO or TMZ cohorts. TMZ (10 mg/kg; Sigma-Aldrich) or DMSO (Sigma-Aldrich) was injected i.p. for next 14 consecutive days, then the mice were euthanized with sodium pentobarbital. The whole brain were carefully dissected and photographed. And tumor samples from core and peripheral regions were dissected for paraffin embedding according to standard procedures. Tissue blocks were prepared for histology and IHC study.
Bioinformatics analyses
Gene ontology (GO) analysis was performed on the Database for Annotation, Visualization and Integrated Discovery (DAVID) to analyze the main function of the differential proteins (27) . We used the 25 identified differential proteins for the query, with the whole human genome as the background. The analysis was performed using the DAVID default parameters.
Statistical analyses
Unpaired, two-tailed Student's t tests were used for analysis of cellular morphological parameters, proliferation index and invasive cells as well as apoptosis rate among experimental groups. Group mean differences were otherwise assessed using one-way analysis of variance (one-way ANOVA) with Turkey post hoc tests to further examine pairwise differences. The 50% inhibitory concentration (IC 50 ) of TMZ was calculated by Bliss method. Survival curves were estimated with the use of the KaplanMeier product-limit method, and survival distributions were compared across groups with the use of the log-rank test.
Results
Isolation and identification of GBM primary cells and single cell clones
In order to identify the phenotypic diversity of GBM cells in core lesions of T1 gadolinium enhancing zone (ECs) and margins of T1 gadolinium enhancing lesions (PNCs), a culture was established from the core and margins lesions of T1 enhancing zone of five patients diagnosed as GBM (Supplementary Figure 1A , available at Carcinogenesis Online). Two morphologically distinct cell strains which were squamous-like and fibroblast-like were isolated from each patient, and length and area of whole cell and length of cell protrusion, length of cell width were determined. We found PNCs exhibited significantly longer cell protrusion and larger cellular area than ECs (P ＜ 0.01; Figure 1A . Subsequently, a phenotype screen was performed to identify morphologically diverse single cell clones from ECs by serial dilution method (Supplementary Figure 1B , available at Carcinogenesis Online). After 2 months, two single cell clones with diverse phenotypic diversity from each patient were selected for further investigation. Analogously, these two cell clones were designated as GCs(H) and GCs(L) according to significant diversity in cellular protrusion and area. GCs(H) manifested much longer cell protrusion and larger cellular area than GCs(L) ( Figure 1B ). All cells were identified by GFAP staining (Supplementary Figure 1B , available at Carcinogenesis Online). Meanwhile, procedures were identically manipulated in five glioma cell lines (U87MG, U251, T98, LN229 and A172) to obtain Each bar represents the mean ± SD of three independent experiments. #P ＞ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001. similar cell clones for comparison. The similar phenotypes were found in different colonies of cell lines (Supplementary Figure 1C , available at Carcinogenesis Online). In U87, the most obvious phenotypic difference was observed. The length of U87(H) protrusion was much longer than U87(L) ( Figure 1C ). In addition, silver staining of these cell strains showed similar protein expression profiles while several bands were apparently different at ~27, ~38, ~57 and ~60kDa ( Figure 1D ).
GBM cell clones with different invasive ability were consistent with diverse EMT status
Since six clones with typical cellular morphological features were obtained, we wonder if the cellular morphology is associated with biological phenotype. Transwell assay and scratch assay were employed simultaneously to determine invasion capacity of sorted clones. Compared with ECs, PNCs cells with longer pseudopod protrusion constantly maintained higher invasiveness. Similar results were also proved in GCs(H) and U87(H) with compared to the GCs(L) and U87(L) (Figure 2A) . Furthermore, to explore whether the diverse invasive ability will be abolished under the treatment of chemo-radiological stress, we utilized TMZ and X-ray radiation as extrinsic stimulation. Interestingly, the different invasion tendencies were unaltered under TMZ administration and X-ray exposure ( Figure 2A ).
As the EMT is an important process during tumor invasion and metastasis, representative biomarkers of epithelium and mesenchyme were determined. The results indicated that in five patients ECs with lower migration rate showed higher expression of T-cadherin and lower expression of N-cadherin level with or without TMZ/X-ray treatment, which hinted higher mesenchymal status of PNCs ( Figure 2B) . Moreover, the similar diverse invasive behavior and EMT status between GCs(H) and GCs(L), U87(H) and U87(L) further disclosed the cellular heterogeneity in GBM ( Figure 2B ). Based on the above data, it is reasonable to hypothesize that PNCs at margins of T1 gadolinium enhancing lesions might origin from GCs(H) inside the core lesions of T1 gadolinium enhancing zone.
GBM cell clones exhibited different proliferation and apoptosis rate
To delimitate the growth patterns of distinct cell clones, cellcounting assay (CCK-8) was performed. Cells were cultured in normal condition or under TMZ stimulation as well as radiation exposure. An exciting phenomena was observed constantly, cell proliferation rates dramatically desynchronized during exponential growth phases, cells with higher invasiveness, PNCs, GCs(H), U87(H), tend to exhibit lower proliferation rate under normal condition (all P ＜ 0.05; Figure 2C ). Whereas the condition was startlingly reversed when administrated by chemotherapy drug or exposed to radiation stimulation (all P ＜ 0.05; Figure 2C ). Moreover, by colony formation assay under normal condition and RT, TMZ treatment, the similar tendency was shown as cell counting assay (Supplementary Figure 2A, available at Carcinogenesis Online). That is to say, highly invasive cells propagated much faster under stimulation, displaying resistance to TMZ strike. However, it should be mentioned that proliferation rate of highly invasive cells were still weakened under these detrimental catastrophe.
Additionally, to further investigate cell cycle distribution of these cells, we utilized flow cytometry to assess cell cycle proportion and apoptosis rate. Similarly, all cells were cultured normally or under TMZ and radiation exposure, respectively. Significantly higher apoptosis rate were observed in PNCs, GCs(H) and U87(H) cell clones in normal condition [apoptosis:
PNCs, 5.1 ± 0.495%; ECs, 2.85 ± 0.212%; GCs(H), 4.5 ± 0.071%; GCs(L), 2.9 ± 0.636%; U87(H), 1.4 ± 0.424%; U87(L), 0.8 ± 0.389%; all P ＜ 0.05; Figure 2D ]. Moreover, higher cycle arrest of PNCs, GCs(H) and U87(H) in normal condition were consistent with higher apoptosis rate (Supplementary Figure 3 , available at Carcinogenesis Online). As predicted, the total apoptosis rate and cell cycle arrest pattern was reversed when cells were treated with TMZ and X-ray ( Figure 2D, Supplementary Figure 3 , available at Carcinogenesis Online).
Proteomics analysis uncovered TPD52L2 as a candidate protein regulating GBM cellular heterogeneity
Cellular phenotypes are tightly parallel with their protein profiles. To gain deeper insights, two-dimensional protein electrophoresis and protein identification based on mass spectrometry technology were utilized to analyzed differential expression signature of GCs(H) versus GCs(L) and U87(H) versus U87(L) ( Figure 4A , available at Carcinogenesis Online). Duplicates with independent samples yielded highly producible protein expression data. We defined proteins whose expression level exceeded two-fold alterations of another and displayed a statistical significance as interesting targets. There was overlap (48.6%, 17/35) between the expression profile of GCs cell clones and profile obtained from U87 cell clones, among which 12 identified proteins were up-regulated in GCs(L) and U87(L) signature while five identified proteins were upregulated in GCs(H) and U87(H) signature (Supplementary Figure 4A , available at Carcinogenesis Online). To further define the biologic processes involving these differential expression signatures, we performed GO enrichment analysis using the DAVID database. Significantly enriched GO terms were clustered according to their functional annotations. Results from the database showed that the top three molecular functional annotations including: phosphoprotein phosphatase activity, structural constituent of cytoskeleton, structural molecular activity (Supplementary Figure 4B , available at Carcinogenesis Online), and the top seven biological process annotations including: dephosphorylation, response to reactive oxygen species, response to inorganic substance, response to oxidative stress, epidermis development, cytoskeleton organization and ectoderm development (Supplementary Figure 4C , available at Carcinogenesis Online). Notably, of all the candidate proteins in the intersection of Venn diagram, TPD52L2, as the leading robustly and consistently identified protein, was selected for deeper investigation. Western blot had demonstrated low expression of TPD52L2 in highly invasive cells, PNCs, GCs(H) and U87(H) ( Figure 3A) . Moreover, IHC of tumor tissue from T1 enhancing zone and immunofluorescence of GCs(H) and GCs(L) verified different TPD52L2 expression subpopulations existed in tumor core ( Figure 3B ). Meanwhile, our IHC results of 25 GBM patients also indicated TPD52L2 showed higher expression in tumor core lesions but lower expression at margins of T1 enhancing zone ( Figure 6A ).
TPD52L2 silencing enhanced GBM cell migration by inducing EMT while decreased cell proliferation rate in vitro
The proteomics analysis intrigued our deeper investigation on functional effects of TPD52L2 in vitro. We employed siRNA and recombinant lentivirus to suppress and overexpress endogenous TPD52L2 (Figure 3C and D) . We focused on the ECs, GCs(L) and U87(L) cells with higher expression of TPD52L2, depletion of the protein by Lv-shTPD52L2 would somehow restore some biological traits of invasive cells. Morphologically, cells endured transformation from squamous shape to spindle shape, companying by significantly prolonged cellular protrusion ( Figure 3E ). We further investigated migration capacity of ECs, GCs(L) and U87(L) cells transfected with Lv-shTPD52L2 by transwell assay and wound healing assay. TPD52L2 silencing dramatically enhanced migration ability of these less invasive cells while TPD52L2 overexpression dramatically decreased migration ability of invasive cells in normal condition (all P ＜ 0.05; Figure 3F ). Likewise, Lv-shTPD52L2 cells of ECs, GCs(L) and U87(L) remained higher migration ability compared with Lv-shCon cells even under TMZ administration (all P ＜ 0.05; Figure 3F ).
GO functional annotation underscored that cytoskeletal rearrangement was a critical biological process in GBM cell heterogeneity (Supplementary Figure 4B and C, available at Carcinogenesis Online), which suggested a possible epithelium mesenchymal transition in cell invasion. Moreover, previous literatures showed that Wnt signaling promotes EMT by inhibiting glycogen synthase kinase-3β (GSK3β) to stabilize β-catenin (28) (29) (30) . To investigate whether TPD52L2 involved in EMT status alterations of GBM cells, we used western blot to detect EMT associated markers. Our data indicated that knockdown of TPD52L2 would significantly enhanced the expression of CTNNB1/β-catenin and SNAI1/Snail while overexpression of TPD52L2 would significantly inhibited the expression of CTNNB1/β-catenin and SNAI1/Snail ( Figure 3G ). Snail is an EMT transcription factor which facilitate EMT activation underscored by a T-cadherin to N-cadherin switch.
Besides, cell proliferation rate were simultaneously determined. Inhibition of TPD52L2 significantly decreased proliferation rate of ECs, GCs(L) and U87(L) while restore their TMZ insensitivity, this condition was reversed in TPD52L2 overexpression group ( Figure 4A ). We then analyzed apoptosis rate of ECs, GCs(L) and U87(L) and their corresponding Lv-shTPD52L2 and TPD52L2 overexpression cells. Our results hinted down regulation of TPD52L2 significantly enhanced cell apoptosis in normal condition, whereas inversely increased their TMZ resistance ( Figure 4B ). Further cell cycle detection revealed ECs, GCs(L) and U87(L) were less likely to endure cell cycle arrest as compared to their Lv-shTPD52L2 cells in normal condition. However, when these cells were treated with TMZ, both ECs, GCs(L) and U87(L) and their Lv-shTPD52L2 cells were arrested in cell cycle, however, ECs, GCs(L) and U87(L) tended to maintain higher arrestment ( Figure 4C ).
TPD52L2 regulate GBM cellular heterogeneity in vivo and impacted prognosis of GBM patients
Given that TPD52L2 would increase GBM cellular heterogeneity, we performed an in vivo tumorigenesis study in nude mice. Clearly, as compared to NC tumors, TPD52L2 overexpression group formed larger tumors than both Lv-shCon and Lv-shTPD52L2 group in normal condition. However, the results were reversed when these nude mice were administrated with TMZ ( Figure 5A, B and E) . Moreover, Lv-shTPD52L2 tumors constantly exhibited obvious invasion features with TMZ administration or not. Observations by HE staining demonstrated Lv-shTPD52L2 U87(L) tumors tended to form jagged islets by invading into neighboring tissues while Lv-shCon and TPD52L2(oe) tumors maintained relative smooth edges ( Figure 5C ). In addition, the expression of mesenchymal markers including N-cadherin, Snail, β-catenin were upregulated greatly when TPD52L2 was inhibited both in normal condition and in TMZ condition and the epithelial marker T-cadherin was conversely downregulated, supporting the induction of the EMT by inhibiting TPD52L2 in vivo ( Figure 5D and E) .
Furthermore, we investigated the influence of TPD52L2 expression in clinical outcome of human GBM patients (Supplementary Table 1 , available at Carcinogenesis Online). Kaplan-Meier survival analysis showed in non-adjuvant chemo-radio therapy cohort (43 patients), no significant difference was observed in overall survival and progress free survival between high TPD52L2 expression and low TPD52L2 expression ( Figure 6B ). However, in cohort (45 patients) received standard radiotherapy plus concomitant and adjuvant TMZ (Stupp strategy), lower expression of TPD52L2 indicated a poorer prognosis ( Figure 6C ).
Discussion
Cellular heterogeneity has been widely studied in various malignant tumors, including GBM, medulloblastoma (31) (32) (33) . Specifically, cellular heterogeneity comprise intratumoral coexistence of cancer cells with different genetic background, different cell subpopulation inside residual GBM cells derived from the tumor resection margin, diversity between tumor core versus residual GBM cells. Previous study has already revealed residual GBM cells after surgical resection could be considered Representative bands of patient ZA7783 was showed. Each bar represents the mean ± SD of three independent experiments. #P ＞ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001.
as distinct malignant subentities, and that their characteristics cannot be predicted by analysis of routinely resected GBM tissue. However, up to date, most experimental analysis and treatment strategies of GBM are mainly based on data acquired from tumor core. Here, we analyzed for the first time the biological phenotypes and proteomics diversity from residual GBM cells and tumor core. The biological traits of residual cells we found is slightly different from Martin Glas (34) , which make us speculate the existence of heterogeneous subpopulations with different genetic background or EMT status inside residual GBM cells.
In this study, we examined the role of TPD52L2 in regulating heterogeneity and the EMT status of GBM. We found that TPD52L2 expression was associated with patient prognosis in GBM and that TPD52L2 impacted GBM cell heterogeneity through regulating EMT status in vitro and in vivo. To be specific, our study has convincedly demonstrated a connection between cellular morphological characteristics and biological phenotypes and unveiled a potential molecular mechanism regulating GBM cell heterogeneity in protein level. Briefly, we observed GBM were composed of morphological distinct cell clones, the main difference focus on length of cellular protrusion, which were verified by determining PNCs, ECs, GCs clones and U87 clones. Wound healing assay and transwell assay of PNCs, ECs suggested cells with longer protrusion showed higher invasive capacity. Moreover, we found similar phenomenon from GCs(H), GCs(L), U87(H) and U87(L), which made us hypothesize that GCs(H) is likely to invade to adjacent tumor tissue and evolved to PNCs. Further studies revealed these higher invasive cells exhibited lower proliferation rate and higher apoptosis rate in normal condition, which were consist with their higher cell cycle arrest. However, the tendency was startlingly reversed when these cells were confronted with X-ray and TMZ. Specifically, when cells exposed to chemo-radio environment, the proliferation rate of cells were simultaneously inhibited to some extent, while these less invasive cells, ECs, GCs(L), U87(L) showed higher sensitivity to chemo-radio stimuli, which were fully demonstrated by higher apoptosis rate and accumulation of cell cycle arrest in less invasive cells.
Our study further indicated the morphological diversity and invasive phenotypes was associated with cellular EMT status. Epithelial to mesenchymal transition (EMT) represents the molecular reprogramming and phenotypic changes involved in the conversion of immotile epithelial cells to motile mesenchymal cells (35) (36) (37) . It severs as a central molecular program enhancing cellular skeleton rearrangement and tumor invasion (9, 38, 39) . Besides, EMT has been reported to involve in chemoresistance and radio-resistance of GBM (40, 41) . We determined expression of mesenchymal and epithelial markers by western blotting and found the higher invasive cells exhibited higher N-cadherin level but lower T-cadherin level. Combined with the flowcytometry results in chemo-radio environment, when cells exposed to X-ray and TMZ, cells with higher N-cadherin expression showed relatively lower apoptosis rate and higher proliferation rate. Therefore, it's rational to predict these higher invasive cells exhibited chemo-radio resistance through regulating EMT status.
Delving deeper, proteomic analysis revealed 35 differential expressed proteins among GCs(H) versus GCs(L) and U87(H) versus U87(L). Further GO analysis indicated the differential expression proteins were mainly clustered in cytoskeleton organization and phosphoprotein phosphatase activity. Since EMT is a process compromising cellular alteration from round shape to spindle shape and multiple signal pathways were activated in this process. These differential expressed proteins, especially for these proteins exerting phosphorylation effects may involve in the activation of specific pathway associated with EMT of GBM cells. Notably, of all the differential expressed proteins identified by mass spectrometry, TPD52L2 has been implicated to promote cell proliferation by interacting with hABCF3 in liver cancer and acted as a negative regulator of migration in oral squamous cell carcinoma (42, 43) . In our study, we found TPD52L2 was closely related with GBM cellular heterogeneity both in vivo and in vitro. Inhibition of TPD52L2 in ECs, GCs(L) and U87(L) enhanced their protrusion length and migration ability while significantly reduced their proliferation rate in normal condition. By withdrawing serum to induce GCs(L) to endure EMT process, we observed TPD52L2 depletion had rare influence on the migration of GCs(L); in contrast, when GCs(L) was cultured in medium containing serum and no EMT process was induced, TPD52L2 depletion would significantly enhanced GCs(L) migration. All these results collectedly demonstrated TPD52L2 is an upstream event of EMT status. Besides, animal studies manifested that as compared with Lv-shCon group, Lv-shTPD52L2 tumors exhibited smaller tumor volume. Interestingly, this condition was abolished by TMZ administration. Under TMZ stress, Lv-shTPD52L2 tumors grew significantly faster and expanded deeper into adjacent tissues than Lv-shCon tumors, which meant inhibiting TPD52L2 expression promoted cell invasion. All these results supported TPD52L2 was essential to induce GBM heterogeneity in vivo and in vitro.
Moreover, we found TPD52L2 impacted cellular heterogeneity by regulating cellular EMT status. During EMT, WNT signaling synergizes with TGF-β family members to foster SNAI1 activation through receptor tyrosine kinases (RTKs) (44) . In canonical WNT signaling, inhibition of GSK3β prevent β-catenin phosphorylation and degradation via ubiquitylation, hence enabling β-catenin translocate to the nucleus to engage the transcription factor SNAI1 and favor mesenchymal associated genes expression (45, 46) . Intriguingly, western blot demonstrated that down regulation of TPD52L2 would increase the expression of N-cadherin by inducing the expression of β-catenin and SNAI1 no matter with TMZ treatment or not. Meanwhile, in the xenograft models, inhibiting TPD52L2 expression dramatically reduced tumor volume but enhancing tumor infiltration to adjacent tissue through increasing SNAI1 nuclear expression and T-cadherin to N-cadherin switch.
Given that low TPD52L2 expression would provide GBM cells with higher proliferation and migration capacity under TMZ stress in vitro and in vivo, we further analyzed the expression of TPD52L2 in tumor specimen. Of note, as compared with very low TPD52L2 level in peripheral 'normal' tissue, higher expression of TPD52L2 was detected in tumor core lesions, which were quite consistent with our data above and further demonstrated cells of higher proliferation rate existed in tumor center while cells of higher migration ability invaded to tumor margins. Furthermore, our results indicated in the GBM cohort only received surgical resection, the TPD52L2 expression have no significant impact on the clinical outcome, while as for patients who received surgical resection and standard radiotherapy plus concomitant and adjuvant TMZ, low TPD52L2 expression indicated the poor prognosis.
Taken together, we provided compelling evidence in our study that TPD52L2 is closely related with cellular heterogeneity in GBM and impacts the prognosis of patients received surgical resection and standard radiotherapy plus concomitant and adjuvant TMZ; we found TPD52L2 primed cell heterogeneity by altering cellular EMT status, which may therefore represent an attractive target for novel molecular therapies for malignant glioma.
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